Alumis (ALMS) · envudeucitinib
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: second half of 2026
we plan to submit an NDA for envu for PsO in the second half of 2026
· filed · SEC filing
After
Stated timing: fourth quarter of 2026
we plan to submit an NDA for envu for PsO in the fourth quarter of 2026
10-Q · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/ALMS-envudeucitinib-2026-08-13, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/ALMS-envudeucitinib-2026-08-13
Alumis (ALMS) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.